Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c1bec4d9586f72ec003182dea7ea94fb |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6813 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
filingDate |
2005-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f4175f95870aa2d37352240de102850 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a75e42802bc142260e26002fd3f65075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d08594131d01de851a94a96dd74769f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_490afcc62a313c760614ec5e5f5ae359 |
publicationDate |
2012-11-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
AU-2005203962-C1 |
titleOfInvention |
Interleukin-12 targeted to oncofoetal fibronectin |
abstract |
The invention provides a compound comprising a target specific portion and an effector portion wherein the target specific portion comprises or consists of a monoclonal antibody having specificity for oncofoetal fibronectin, or a fragment or variant thereof which retains the antigen binding specificity of the parent monoclonal antibody and the effector portion comprises or consists of interleukin-12, or a functional fragment or variant thereof, characterised in the monoclonal antibody having specificity for oncofoetal fibronectin binds to a region of oncofoetal fibronectin other than the ED-B region. The invention further provides nucleic acids encoding the compounds of the invention, and the use of such compounds in medicine, e.g. in the treatment of cancer. |
priorityDate |
2004-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |